Natco launches hepatitis C drug Hepcinat LP in Nepal
Hepcinat LP, a two-drug fixed-dose combination product that contains ledipasvir and sofosbuvir, is the generic version of Gilead Sciences' Harvoni drug
 "Natco launches hepatitis C drug Hepcinat LP in Nepal")
Natco Pharma Limited launched the first licensed generic version of ledipasvir & sofosbuvir combination in Nepal, under its brand name Hepcinat LP, on October 28, 2015.
Hepcinat LP is a two-drug fixed-dose combination product that contains 90 mg of ledipasvir and 400 mg of sofosbuvir in a single tablet, and sold globally by Gilead Sciences Inc, under its brand Harvoni.
It is indicated for the treatment of chronic hepatitis C genotype 1 infection in adults. Natco has priced its generic medicine, Hepcinat LP, at an MRP of Rs 25,000 for a bottle of 28 tablets in Nepal.
Natco had signed a non-exclusive licensing agreement with Gilead Sciences earlier in 2015, to manufacture and sell generic versions of its chronic hepatitis C medicines, including generic version of Harvoni, in India and other 100 developing countries.
Hepcinat LP is a two-drug fixed-dose combination product that contains 90 mg of ledipasvir and 400 mg of sofosbuvir in a single tablet, and sold globally by Gilead Sciences Inc, under its brand Harvoni.
It is indicated for the treatment of chronic hepatitis C genotype 1 infection in adults. Natco has priced its generic medicine, Hepcinat LP, at an MRP of Rs 25,000 for a bottle of 28 tablets in Nepal.
Natco had signed a non-exclusive licensing agreement with Gilead Sciences earlier in 2015, to manufacture and sell generic versions of its chronic hepatitis C medicines, including generic version of Harvoni, in India and other 100 developing countries.
Don't miss the most important news and views of the day. Get them on our Telegram channel
First Published: Oct 29 2015 | 3:07 PM IST